美国医保打包付费改革与维持性血透患者维生素D使用的关联:中断时间序列分析
该中断时间序列分析基于2008-2013年美国肾脏数据系统,评估2011年医保前瞻性支付系统(PPS)实施与血透患者静脉维生素D类似物使用的关系。在359,600名 prevalent 血透患者中,PPS实施后静脉维生素D类似物平均剂量立即下降7%(-13.5 μg/季度,P<0.001), incident 患者起始剂量立即下降0.40 μg(P<0.001),维生素D治疗启动率立即下降4.5/100人月(P<0.001)。
要点
- PPS实施与 prevalent 血透患者静脉维生素D类似物平均剂量立即下降7%相关
- PPS实施与 incident 血透患者起始剂量立即下降0.40 μg相关
- PPS实施与维生素D治疗启动率立即下降4.5/100人月相关
核心结论
- PPS实施与静脉维生素D类似物平均剂量和起始剂量下降7%以及维生素D治疗启动率下降10%相关。
研究设计与样本
- 中断时间序列分析,纳入2008-2013年美国肾脏数据系统中成人血透患者,暴露为PPS实施。
主要发现
- 在359,600名 prevalent 血透患者中,静脉维生素D类似物占总使用量的99%,该趋势随时间不变。
- PPS实施后静脉维生素D类似物平均剂量立即下降13.5 μg/季度(基线186.5 μg/季度,P<0.001),斜率变化0.43/季度(P=0.3)。
- incident 血透患者起始剂量立即下降0.40 μg(基线5.22 μg,P<0.001),斜率变化-0.03/季度(P=0.03)。
- 在99,970名 incident 血透患者中,维生素D治疗启动率基线为44.9/100人月,PPS前已呈下降趋势(β=-0.46/100人月,P<0.001),PPS实施后立即下降4.5/100人月(P<0.001),斜率变化-0.19/100人月(P=0.2)。
临床怎么用
- 肾内科医生在血透患者管理中应关注医保支付政策变化对静脉维生素D使用模式的潜在影响。
局限性
- incident 血透患者仅限65岁及以上人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & RATIONALE: Medicare's 2011 prospective payment system (PPS) was introduced to curb overuse of separately billable injectable drugs. After epoietin, intravenous (IV) vitamin D analogues are the biggest drug cost drivers in hemodialysis (HD) patients, but the association between PPS introduction and vitamin D therapy has been scarcely investigated. STUDY DESIGN: Interrupted time-series analyses. SETTING & PARTICIPANTS: Adult US HD patients represented in the US Renal Data System between 2008 and 2013. EXPOSURES: PPS implementation. OUTCOMES: The cumulative dose of IV vitamin D analogues (paricalcitol equivalents) per patient per calendar quarter in prevalent HD patients. The average starting dose of IV vitamin D analogues and quarterly rates of new vitamin D use (initiations/100 person-months) in incident HD patients within 90 days of beginning HD therapy. ANALYTICAL APPROACH: Segmented linear regression models of the immediate change and slope change over time of vitamin D use after PPS implementation. RESULTS: Among 359,600 prevalent HD patients, IV vitamin D analogues accounted for 99% of the total use, and this trend was unchanged over time. PPS resulted in an immediate 7% decline in the average dose of IV vitamin D analogues (average baseline dose = 186.5 μg per quarter; immediate change = -13.5 μg [P < 0.001]; slope change = 0.43 per quarter [P = 0.3]) and in the starting dose of IV vitamin D analogues in incident HD patients (average baseline starting dose = 5.22 μg; immediate change = -0.40 μg [P < 0.001]; slope change = -0.03 per quarter [P = 0.03]). The baseline rate of vitamin D therapy initiation among 99,970 incident HD patients was 44.9/100 person-months and decreased over time, even before PPS implementation (pre-PPS β = -0.46/100 person-months [P < 0.001]; slope change = -0.19/100 person-months [P = 0.2]). PPS implementation was associated with an immediate change in initiation levels (by -4.5/100 person-months; P < 0.001). LIMITATIONS: Incident HD patients were restricted to those 65 years or older. CONCLUSION: PPS implementation was associated with a 7% reduction in the average dose and starting dose of IV vitamin D analogues and a 10% reduction in the rate of vitamin D therapy initiation.
引用
- Spoendlin J, Schneeweiss S, Tsacogianis T, et al. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. Am J Kidney Dis. 2018. PMID: 29891194. doi:10.1053/j.ajkd.2018.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。